AZD9291的专利WO2013014448A12-(2,4,5-substituted-anilino)pyrimidinederivativesasegfrmodulatorsusefulfortreatingcancerFigure1.AZ口Figure1.AZ口9201significantlydelaysresistanceinEGFR-mutantPCO(EGFRexon19ctelatiQn)cellsinvitroTimetoresistance(days)Figure2.DetectionofT790MresistanceinEGFR^TKI-treatedPC9cell0ne&...
Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo) 机译:Osimertinib(AZD9291),不可逆的第三代TKI,在具有最普遍的EGFR Ex20Ins的NSCLC临床前模型中(体外和体内)诱导...
药物简介:AZD9291 是口服不可逆的,选择性的突变体EGFR抑制剂,其对外显子19缺失的 EGFR, L858R/T790M EGFR,和 WT EGFR的IC50分别为12.92, 11.44 和493.8 nM。体外研究:AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro.体内研究:AZD...
AZD9291 是口服不可逆的,选择性的突变体EGFR抑制剂，其对外显子19缺失的 EGFR, L858R/T790M EGFR,和 WT EGFR的IC50分别为12.92, 11.44 和493.8 nM。体外研究：AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro.体内...
98 - Osimertinib (AZD9291), an irreversible 3rd generation TKI, induces tumor growth inhibition in NSCLC pre-clinical models harboring the most prevalent EGFR Ex20Ins (in vitro and in vivo)The winners of the Malcolm Campbell Memorial Prize for 2017 discuss the structure-guided discovery of ...
In VitroOsimertinib (AZD-9291) shows similar potency to early generation tyrosine kinase inhibitor (TKIs) in inhibiting EGFR phosphorylation in EGFR cells harboring sensitising EGFR mutants including PC-9 (ex19del), H3255 (L858R) and H1650 (ex19del), with mean IC50 values ranging from 13 to ...
(MDR)incertaintypesofcancer.Inourstudy,weinvestigatedwhetherosimertinib(AZD9291),athird-generationirreversibletyrosinekinaseinhibitorofbothactivatingEGFRmutationsandresistance-associatedT790Mpointmutation,couldreverseMDRinducedbyABCB1andABCG2invitro,invivo,andexvivo.Ourresultsshowedthatosimertinibsignificantlyincreased...
AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. 体内研究:AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosph...
Osimertinib (AZD9291) is an oral, irreversible, and mutant-selectiveEGFRinhibitor withIC50of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.In vitro AZD9291 shows significantly more potent inhibition of proliferation in ...
剂量换算:临床量/非正版量=1 : 1.2,那么40mg AZD9291=48mg ,80mg AZD929仁96mg Figure 1 r AZD9291 significantly delays ngistance in EGFR-mutant PC9 (EGFR eson 19 deletion) cells in vitro nib n=6 ? Atatini n=5 丄l WZ4O2 r-6 ? AZD9291 n:Q Irrflai ccrknflnfrstion wjir 审甲wlI ...